

VIRAGEN INC  
Form 8-K  
December 31, 2003

**Table of Contents**

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **December 23, 2003**

**Viragen, Inc.**

---

(Exact name of registrant as specified in its charter)

**Delaware**

---

(State or other  
jurisdiction of  
incorporation)

**001-15823**

---

(Commission File  
Number)

**59-2101668**

---

(IRS Employer  
Identification  
No.)

**865 SW 78th Avenue, Suite 100, Plantation, Florida**

---

(Address of principal executive offices)

**33324**

---

(Zip Code)

Registrant's telephone number, including area code: **(954) 233-8746**

Not applicable

---

(Former name or former address, if changed since last report)

---

---

---

**TABLE OF CONTENTS**

Items 1 – 4. Not Applicable

Item 5. Other Events and Regulation FD Disclosure

Item 6. Not Applicable

Item 7. Exhibits

Items 8 – 12. Not Applicable

**SIGNATURES**

Press Release dated December 30, 2003

Securities Purchase Agreement

Registrations Rights Agreement

Form of Common Stock Purchase Warrant

---

**Table of Contents**

**Items 1 4. Not Applicable**

**Item 5. Other Events and Regulation FD Disclosure**

On December 30, 2003, Viragen, Inc. issued a press release announcing that it had consummated the transactions under a Securities Purchase Agreement and sold an aggregate of \$4,550,000 of its common stock to several institutional investors. The shares of common stock were purchased at a price of \$0.20 per share. In addition, Viragen issued three-year warrants to purchase a total of 6.83 million shares of its common stock at \$0.26 per share.

Viragen paid \$295,750 and issued a three-year warrant to purchase 182,000 shares of its common stock at \$0.20 per share, as a fee to the finder for this transaction. In addition, Viragen agreed to file a registration statement covering the shares issued and issuable under the Securities Purchase Agreement within 30 days following the closing.

The text of the press release, the Securities Purchase Agreement and certain related attachments are included as exhibits to this Form 8-K.

**Item 6. Not Applicable**

**Item 7. Exhibits**

- 99.1 Press release dated December 30, 2003
- 99.2 Securities Purchase Agreement dated as of December 23, 2003 between Viragen, Inc. and the purchasers listed in the agreement
- 99.3 Registration Rights Agreement entered into as of December 23, 2003, between Viragen, Inc. and the purchasers listed in the agreement
- 99.4 Form of common stock purchase warrant entered into as of December 23, 2003

**Items 8 12. Not Applicable**

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**VIRAGEN, INC.**

Date: December 30, 2003

By: /s/ Dennis W. Healey

---

Dennis W. Healey  
Executive Vice President and Principal Financial Officer